Ongoing clinical trials and approved products targeting T-cell activation, in radioligand therapy and PET/SPECT imaging. Data as of 26 October 2026.
| Trial | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
| [18F]F-AraGNCT04815096 · Bacterial infections | Phase 2 | Recruiting | CellSight Technologies, Inc. | 1 |
| [18F]F-AraGNCT06107374 · Small-cell lung cancer | Phase 2 | Recruiting | CellSight Technologies, Inc. | 1 |
| [18F]F-AraGNCT03684655 · Bacterial infections | Phase 2 | Recruiting | CellSight Technologies, Inc. | 1 |
| [18F]F-AraGNCT07611357 · Alzheimer's disease and cognitive disorders | Phase 2 | Not yet recruiting | CellSight Technologies, Inc. | 0 |
| [18F]F-AraGNCT06084806 · Small-cell lung cancer | Phase 2 | Recruiting | CellSight Technologies, Inc. | 1 |
| [18F]F-AraGNCT00004847 · Pheochromocytoma / paraganglioma | Phase 1 | Recruiting | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 1 |
| [18F]F-AraGNCT07076862 · Bacterial infections | Phase 1 | Recruiting | University of California, Davis | 1 |
| [18F]F-AraGNCT07168785 · Head and neck | Phase 1 | Not yet recruiting | Indiana University | 1 |
| iRelate · [18F]F-AraGNCT06457789 · Small-cell lung cancer | No phase | Recruiting | Amsterdam UMC, location VUmc | 1 |
| SHARP · [18F]F-AraGNCT05701176 · Small-cell lung cancer | No phase | Recruiting | Amsterdam UMC, location VUmc | 1 |
| ATTAIN · [18F]F-AraGNCT05157659 · Small-cell lung cancer | No phase | Active, not recruiting | Amsterdam UMC, location VUmc | 1 |
T-cell activation. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 26 October 2026. https://theranosticatlas.com/target/t-cell-activation/ (accessed [date]).
A monitoring tool with no regulatory value: check every item at its source.